AI Portfolio Summary
In 2024 Q3, Ghost Tree Capital, LLC maintained a portfolio of 75 distinct positions. The most significant new addition to the portfolio was SPDR SER TR, which now represents 8.95% of the total fund value. The fund also reduced its exposure to VIRIDIAN THERAPEUTIC by 87.2%.
Total Positions
75
Quarter
2024 Q3
Top Holding
XBI (9.0%)
Top 10 Concentration
42.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 75
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
XBI
PUT
SPDR SER TR
|
PUT Option | 8.95% | — |
#1
Prev: #—
|
9.1 | 300,000 | no change |
NEW
|
300,000 | $29,640,000 | 2015 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
N/A
BIOHAVEN LTD
|
—
|
Unknown | 5.26% | — |
#2
Prev: #—
|
7.1 | 348,778 | no change |
NEW
|
348,778 | $17,428,437 | — | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | ||
|
SRPT
SAREPTA THERAPE...
|
Healthcare | 4.53% | 2.72% |
#3
10
Prev: #13
|
5.8 | 65,000 | 118.2% |
P
S
|
120,000 | $14,986,800 | 2015 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
NVO
NOVO-NORDISK A ...
|
Healthcare | 3.96% | — |
#4
Prev: #—
|
5.6 | 110,000 | no change |
NEW
|
110,000 | $13,097,700 | 2024 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
BPMC
BLUEPRINT MEDIC...
|
Unknown | 3.91% | 1.35% |
#5
24
Prev: #29
|
5.1 | 100,000 | 250.0% |
P
S
|
140,000 | $12,950,000 | 2017 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 3.66% | 3.78% |
#6
Prev: #6
|
2.0 | -15,000 | -10.0% |
P
S
|
135,000 | $12,132,450 | 2019 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 3.48% | 2.00% |
#7
12
Prev: #19
|
3.9 | 115,000 | 48.9% |
P
S
|
350,000 | $11,511,500 | 2021 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
CATX
PERSPECTIVE THE...
|
Healthcare | 3.02% | 2.89% |
#8
3
Prev: #11
|
1.7 | -175,000 | -18.9% |
P
S
|
750,000 | $10,012,500 | 2024 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 2.85% | 2.57% |
#9
5
Prev: #14
|
1.6 | -10,000 | -3.8% |
P
S
|
250,000 | $9,432,500 | 2024 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
ROIV
ROIVANT SCIENCE...
|
Healthcare | 2.79% | 3.31% |
#10
Prev: #10
|
1.1 | -200,000 | -20.0% |
P
S
|
800,000 | $9,232,000 | 2023 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 2.76% | 3.55% |
#11
3
Prev: #8
|
1.1 | -70,000 | -46.7% |
P
S
|
80,000 | $9,141,600 | 2021 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
VKTX
VIKING THERAPEU...
|
Healthcare | 2.68% | 1.58% |
#12
14
Prev: #26
|
3.6 | 45,000 | 47.4% |
P
S
|
140,000 | $8,863,400 | 2022 Q4 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 2.62% | 2.25% |
#13
4
Prev: #17
|
3.5 | 100,000 | 28.6% |
P
S
|
450,000 | $8,662,500 | 2017 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
JANX
JANUX THERAPEUT...
|
Healthcare | 2.61% | 0.66% |
#14
28
Prev: #42
|
4.0 | 140,000 | 280.0% |
P
S
|
190,000 | $8,631,700 | 2024 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 2.37% | 3.70% |
#15
8
Prev: #7
|
0.9 | -34,221 | -39.5% |
P
S
|
52,500 | $7,838,775 | 2015 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
CRNX
CRINETICS PHARM...
|
Healthcare | 2.32% | 3.37% |
#16
7
Prev: #9
|
0.9 | -90,000 | -37.5% |
P
S
|
150,000 | $7,665,000 | 2021 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 2.29% | 3.83% |
#17
12
Prev: #5
|
0.9 | -150,000 | -50.0% |
P
S
|
150,000 | $7,573,500 | 2023 Q4 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
TGTX
TG THERAPEUTICS...
|
Healthcare | 2.19% | 2.79% |
#18
6
Prev: #12
|
0.9 | -190,000 | -38.0% |
P
S
|
310,000 | $7,250,900 | 2018 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
RZLT
REZOLUTE INC
|
Healthcare | 2.16% | 1.91% |
#19
2
Prev: #21
|
1.4 | 53,494 | 3.8% |
P
S
|
1,474,995 | $7,153,726 | 2024 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 2.05% | 1.94% |
#20
Prev: #20
|
0.8 | -225,000 | -37.5% |
P
S
|
375,000 | $6,780,000 | 2023 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 1.96% | 4.13% |
#21
17
Prev: #4
|
0.8 | -171,589 | -57.2% |
P
S
|
128,411 | $6,474,483 | 2022 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 1.93% | 1.86% |
#22
Prev: #22
|
1.3 | -15,000 | -2.7% |
P
S
|
535,000 | $6,387,900 | 2024 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 1.85% | 2.15% |
#23
5
Prev: #18
|
1.2 | -45,000 | -17.3% |
P
S
|
215,000 | $6,129,650 | 2019 Q4 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
INSM
INSMED INC
|
Healthcare | 1.65% | 1.36% |
#24
4
Prev: #28
|
2.7 | 10,000 | 15.4% |
P
S
|
75,000 | $5,475,000 | 2013 Q4 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 1.57% | — |
#25
Prev: #—
|
4.1 | 195,000 | no change |
NEW
|
195,000 | $5,204,550 | 2024 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
REPL
REPLIMUNE GROUP...
|
Healthcare | 1.49% | 1.27% |
#26
6
Prev: #32
|
1.6 | no change | no change |
P
S
|
450,000 | $4,932,000 | 2023 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
CRBP
PUT
CORBUS PHARMACE...
|
PUT Option | 1.37% | — |
#27
Prev: #—
|
4.0 | 220,000 | no change |
NEW
|
220,000 | $4,538,600 | 2016 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 1.35% | 1.11% |
#28
7
Prev: #35
|
3.0 | 35,000 | 25.0% |
P
S
|
175,000 | $4,455,500 | 2023 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 1.31% | 0.88% |
#29
10
Prev: #39
|
3.5 | 900,000 | 72.0% |
P
S
|
2,150,000 | $4,321,500 | 2023 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
RYTM
RHYTHM PHARMACE...
|
Healthcare | 1.25% | 1.51% |
#30
3
Prev: #27
|
0.5 | -38,546 | -32.8% |
P
S
|
78,842 | $4,130,532 | 2017 Q4 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
ANNX
ANNEXON INC
|
Healthcare | 1.16% | 0.48% |
#31
17
Prev: #48
|
3.5 | 340,000 | 109.7% |
P
S
|
650,000 | $3,848,000 | 2024 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
KRRO
KORRO BIO INC
|
Healthcare | 1.11% | 1.06% |
#32
4
Prev: #36
|
2.4 | 10,000 | 10.0% |
P
S
|
110,000 | $3,676,200 | 2024 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
INSM
CALL
INSMED INC
|
CALL Option | 1.10% | 4.20% |
#33
30
Prev: #3
|
0.4 | -150,000 | -75.0% |
P
S
|
50,000 | $3,650,000 | 2013 Q4 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 1.09% | — |
#34
Prev: #—
|
3.9 | 100,000 | no change |
NEW
|
100,000 | $3,592,000 | 2024 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
ARVN
ARVINAS INC
|
Healthcare | 1.08% | 0.63% |
#35
8
Prev: #43
|
3.4 | 70,000 | 93.3% |
P
S
|
145,000 | $3,571,350 | 2018 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
CRBP
CORBUS PHARMACE...
|
Healthcare | 1.00% | 2.48% |
#36
21
Prev: #15
|
0.9 | -15,000 | -8.6% |
P
S
|
160,000 | $3,300,800 | 2016 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
HLXB
HELIX ACQUISITI...
|
Unknown | 0.95% | 0.96% |
#37
1
Prev: #38
|
1.4 | no change | no change |
P
S
|
300,000 | $3,134,988 | 2024 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
NUVB
NUVATION BIO IN...
|
Healthcare | 0.93% | 1.05% |
#38
1
Prev: #37
|
2.4 | 200,000 | 17.4% |
P
S
|
1,350,000 | $3,091,500 | 2021 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
SVRA
SAVARA INC
|
Healthcare | 0.93% | 1.33% |
#39
9
Prev: #30
|
0.4 | -325,876 | -31.0% |
P
S
|
725,000 | $3,074,000 | 2023 Q4 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
TNYA
TENAYA THERAPEU...
|
Healthcare | 0.87% | 1.31% |
#40
9
Prev: #31
|
2.3 | 150,000 | 11.1% |
P
S
|
1,500,000 | $2,895,000 | 2024 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
RGNX
REGENXBIO INC
|
Healthcare | 0.84% | 0.62% |
#41
3
Prev: #44
|
3.3 | 95,000 | 55.9% |
P
S
|
265,000 | $2,779,850 | 2015 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 0.80% | — |
#42
Prev: #—
|
3.8 | 500,000 | no change |
NEW
|
500,000 | $2,640,000 | 2024 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
ABSI
ABSCI CORPORATI...
|
Healthcare | 0.63% | — |
#43
Prev: #—
|
3.8 | 550,000 | no change |
NEW
|
550,000 | $2,101,000 | 2024 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
NGNE
NEUROGENE INC
|
Healthcare | 0.63% | 0.80% |
#44
3
Prev: #41
|
0.3 | -20,000 | -28.6% |
P
S
|
50,000 | $2,098,000 | 2024 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
CAPR
CAPRICOR THERAP...
|
Healthcare | 0.57% | — |
#45
Prev: #—
|
3.7 | 125,000 | no change |
NEW
|
125,000 | $1,901,250 | 2024 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
APLS
APELLIS PHARMAC...
|
Healthcare | 0.57% | 1.62% |
#46
21
Prev: #25
|
0.2 | -70,000 | -51.9% |
P
S
|
65,000 | $1,874,600 | 2018 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
SMMT
SUMMIT THERAPEU...
|
Healthcare | 0.56% | — |
#47
Prev: #—
|
3.7 | 85,000 | no change |
NEW
|
85,000 | $1,861,500 | 2024 Q3 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 0.53% | 1.84% |
#48
25
Prev: #23
|
0.2 | -190,237 | -76.0% |
P
S
|
60,000 | $1,764,600 | 2024 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 0.52% | 2.39% |
#49
33
Prev: #16
|
0.2 | -512,708 | -87.2% |
P
S
|
75,000 | $1,706,250 | 2021 Q1 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) | |||
|
PRQR
PROQR THRAPEUTI...
|
Healthcare | 0.49% | 0.47% |
#50
1
Prev: #49
|
0.7 | -12,300 | -1.4% |
P
S
|
887,700 | $1,615,614 | 2024 Q2 | 13F Filing | 2024-09-30 | 2024-11-14 (Est.) |
Showing 1-50 of 75 holdings